[1] Duan ZJ, Li JS, Zhang J, et al. Expert consensus on immunoprophylaxis of childhood rotavirus gastroenteritis (2024 version). Chin J Vaccin Immun, 2024; 30, 95−126. (In Chinese)
[2] Centers for Disease Control and Prevention(US). Transmission of rotavirus. https://www.cdc.gov/rotavirus/about/index.html. [2024-06-12]
[3] World Health Organization. Rotavirus vaccines: WHO position paper-July 2021. Weekly Epidemiol Rec, 2021; 96, 301−20.
[4] World Health Organization. WHO immunological basis for immunization series: module 21: rotavirus. https://www.who.int/publications/i/item/who-immunological-basis-for-immunization-series-module-21-rotavirus. [2024-06-13]
[5] Fang ZY, Zhang LJ, Tang JY, et al. Rotavirus diarrhea among Children in Lulong County, Hebei Province, China. Chin J Virol, 2005; 21, 21−6. (In Chinese)
[6] Zhang J, Duan ZJ, Payne DC, et al. Rotavirus-specific and overall diarrhea mortality in Chinese Children Younger than 5 years: 2003 to 2012. Pediatr Infect Dis J, 2015; 34, e233−7. doi:  10.1097/INF.0000000000000799
[7] Feng LR, Zhao Q. Analysis of bacterial spectrum and drug resistance changes in children with infectious diarrhea in Shanxi Children’s Hospital from 2014 to 2019. J Clin Med Prac, 2021; 25, 45−8,53. (In Chinese)
[8] Luo HM, Ran L, Meng L, et al. Analysis of epidemiological characteristics of report cases of rotavirus diarrhea in children under 5 years old in China, 2005-2018. Chi J Prev Med, 2020; 54, 181−6. (In Chinese)
[9] Li Y, Wang SJ, Liang F, et al. Prevalence and genetic diversity of rotavirus among children under 5 years of age in China: a meta-analysis. Front Immunol, 2024; 15, 1364429. doi:  10.3389/fimmu.2024.1364429
[10] World Health Organization. Introduction of Rotavirus vaccine. https://immunizationdata.who.int/global/wiise-detail-page/introduction-of-rotavirus-vaccine?ISO_3_CODE=&YEAR=;2024. [2024-05-23]
[11] Yuan QL, Cao ZQ, Ji WY, et al. Rotavirus vaccine coverage among children born in Beijing from 2017 to 2022. Mod Pre Med, 2024; 51, 2770−3. (In Chinese)
[12] Lu J, Guan BC, Zhang LP, et al. Rotavirus vaccine coverage in the 2013-2020 birth cohorts in Minhang district of Shanghai. Chin J Vacc Immun, 2021; 27, 695−9. (In Chinese)
[13] Ma WJ, Wei ZQ, Guo JY, et al. Effectiveness of pentavalent rotavirus vaccine in Shanghai, China: a test-negative design study. J Pediatr, 2023; 259, 113461. doi:  10.1016/j.jpeds.2023.113461
[14] Huang YC, Wu FT, Huang YC, et al. Long-term effectiveness of pentavalent and monovalent rotavirus vaccines against hospitalization in Taiwan children. Vaccine, 2020; 38, 6435−41. doi:  10.1016/j.vaccine.2020.07.067
[15] Yi Y, Liu J, Zhang YT, et al. Effectiveness of Lanzhou lamb rotavirus vaccine and RotaTeq against hospitalized rotavirus infections among children during 2020-2023 in Guangdong Province, China: a test-negative case-control study. Infect Dis Ther, 2024; 13, 2301−17. doi:  10.1007/s40121-024-01040-y
[16] McMurry R, Lenehan P, Awasthi S, et al. Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines. Med, 2021; 2, 965-78. e5.
[17] Bellino S, Piovesan C, Bella A, et al. Determinants of vaccination uptake, and influenza vaccine effectiveness in preventing deaths and hospital admissions in the elderly population; Treviso, Italy, 2014/2015-2016/2017 seasons. Hum Vaccin Immunother, 2020; 16, 301−12. doi:  10.1080/21645515.2019.1661754
[18] Lee CH, Yoon HJ. Medical big data: promise and challenges. Kidney Res Clin Pract, 2017; 36, 3−11. doi:  10.23876/j.krcp.2017.36.1.3
[19] Meng RG, Yang Y, Zhang LX. Approaches and prospects on data quality assessment of big data in health and medicine. Chin J Health Inf Manag, 2019; 16, 677−81. (In Chinese)
[20] Zimmerman RK, Patricia Nowalk M, Dauer K, et al. Vaccine effectiveness of recombinant and standard dose influenza vaccines against influenza related hospitalization using a retrospective test-negative design. Vaccine, 2023; 41, 5134−40. doi:  10.1016/j.vaccine.2023.06.056
[21] World Health Organization. Evaluation of COVID-19 vaccine effectiveness. https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccine_effectiveness-measurement-2021.1. [2024-05-23]
[22] Belongia EA, Simpson MD, King JP, et al. Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies. Lancet Infect Dis, 2016; 16, 942−51. doi:  10.1016/S1473-3099(16)00129-8
[23] Rosa RG, Falavigna M, Manfio JL, et al. BNT162b2 mRNA COVID-19 against symptomatic Omicron infection following a mass vaccination campaign in southern Brazil: a prospective test-negative design study. Vaccine, 2023; 41, 5461−8. doi:  10.1016/j.vaccine.2023.07.038
[24] Mujuru HA, BurnettE, Nathoo KJ, et al. Monovalent rotavirus vaccine effectiveness against rotavirus hospitalizations among children in Zimbabwe. Clin Infect Dis, 2019; 69, 1339−44. (In Chinese) doi:  10.1093/cid/ciy1096
[25] World Health Organization. Generic protocol for monitoring impact of rotavirus vaccination on gastroenteritis disease burden and viral strains. https://iris.who.int/handle/10665/69913. [2024-05-23]
[26] Rogawski ET, Platts-Mills JA, Colgate ER, et al. Quantifying the impact of natural immunity on rotavirus vaccine efficacy estimates: a clinical trial in Dhaka, Bangladesh (PROVIDE) and a simulation study. J Infect Dis, 2018; 217, 861−8. doi:  10.1093/infdis/jix668
[27] World Health Organization. WHO target product profiles for COVID-19 vaccines. revised version April 2022. https://www.who.int/publications/m/item/who-target-product-profiles-for-covid-19-vaccines. [2025-05-07]
[28] Ye FX, Xia LS. Sample sizes requirements for studies estimating vaccine efficacy in preventive trials. Mod Pre Med, 2001; 28, 31−3. (In Chinese)
[29] D'Agostino RB, Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med, 1998; 17, 2265−81. doi:  10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B
[30] Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med, 2006; 354, 23−33. doi:  10.1056/NEJMoa052664
[31] Zaman K, Anh D D, Victor JC, et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet, 2010; 37, 615−23.
[32] Mo ZJ, Mo Y, Li MQ, et al. Efficacy and safety of a pentavalent live human-bovine reassortant rotavirus vaccine (RV5) in healthy Chinese infants: a randomized, double-blind, placebo-controlled trial. Vaccine, 2017; 35, 5897−904. doi:  10.1016/j.vaccine.2017.08.081
[33] Burnett E, Parashar UD, Tate JE. Global impact of rotavirus vaccination on diarrhea hospitalizations and deaths among children <5 years old: 2006-2019. J Infect Dis, 2020; 222, 1731−9. doi:  10.1093/infdis/jiaa081
[34] Lin LF. Bias caused by sampling error in meta-analysis with small sample sizes. PLoS One, 2018; 13, e0204056. doi:  10.1371/journal.pone.0204056
[35] Li JX, Wang H, Li DD, et al. Infection status and circulating strains of rotaviruses in Chinese children younger than 5-years old from 2011 to 2018: systematic review and meta-analysis. Hum Vaccin Immunother, 2021; 17, 1811−7. doi:  10.1080/21645515.2020.1849519
[36] Zhao H, Huang W, Xie WJ, et al. Pathogenic surveillance of virus diarrhea in Chongqing in 2018-2019. J Public Health Prev Med, 2023; 34, 68−71. (In Chinese)
[37] Jiang JY, Liang D, Wang L, et al. Epidemiological surveillance: genetic diversity of rotavirus group a in the Pearl River Delta, Guangdong, China in 2019. Biomed Environ Sci, 2024; 37, 278−93.
[38] Tian Y, Shen LY, Li WH, et al. Major changes in prevalence and genotypes of rotavirus diarrhea in Beijing, China after RV5 rotavirus vaccine introduction. J Med Virol, 2024; 96, e29650. doi:  10.1002/jmv.29650
[39] Zhou X, Wang YH, Chen N, et al. Surveillance of human rotaviruses in Wuhan, China (2019-2022): whole-genome analysis of emerging DS-1-like G8P[8] rotavirus. Int J Mol Sci, 2023; 24, 12189. doi:  10.3390/ijms241512189
[40] Naylor C, Lu M, Haque R, et al. Environmental enteropathy, oral vaccine failure and growth faltering in infants in bangladesh. EBioMedicine, 2015; 2, 1759−66. doi:  10.1016/j.ebiom.2015.09.036
[41] Clark A, Tate J, Parashar U, et al. Mortality reduction benefits and intussusception risks of rotavirus vaccination in 135 low-income and middle-income countries: a modelling analysis of current and alternative schedules. Lancet Glob Health, 2019; 7, e1541−52. doi:  10.1016/S2214-109X(19)30412-7
[42] Sun ZW, Fu Y, Lu HL, et al. Association of rotavirus vaccines with reduction in rotavirus gastroenteritis in children younger than 5 years: a systematic review and meta-analysis of randomized clinical trials and observational studies. JAMA Pediatr, 2021; 175, e210347. doi:  10.1001/jamapediatrics.2021.0347
[43] Cortese MM, Leblanc J, White KE, et al. Leveraging state immunization information systems to measure the effectiveness of rotavirus vaccine. Pediatrics, 2011; 128, e1474−81. doi:  10.1542/peds.2011-1006
[44] Staat MA, Payne DC, Donauer S, et al. Effectiveness of pentavalent rotavirus vaccine against severe disease. Pediatrics, 2011; 128, e267−75. doi:  10.1542/peds.2010-3722
[45] Wang FT, Mast TC, Glass RJ, et al. Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States. Pediatr Infect Dis J, 2013; 32, 278−83. doi:  10.1097/INF.0b013e318275328f
[46] Payne DC, Selvarangan R, Azimi PH, et al. Long-term consistency in rotavirus vaccine protection: RV5 and RV1 vaccine effectiveness in US children, 2012–2013. Clin Infect Dis, 2015; 61, 1792−9. doi:  10.1093/cid/civ872
[47] Clark A, Van Zandvoort K, Flasche S, et al. Efficacy of live oral rotavirus vaccines by duration of follow-up: a meta-regression of randomised controlled trials. Lancet Infect Dis, 2019; 19, 717−27. doi:  10.1016/S1473-3099(19)30126-4
[48] Payne DC, Boom JA, Staat MA, et al. Effectiveness of pentavalent and monovalent rotavirus vaccines in concurrent use among US children <5 years of age, 2009-2011. Clin Infect Dis, 2013; 57, 13−20. doi:  10.1093/cid/cit164
[49] Iwata S, Nakata S, Ukae S, et al. Efficacy and safety of pentavalent rotavirus vaccine in Japan: a randomized, double-blind, placebo-controlled, multicenter trial. Hum Vaccin Immunother, 2013; 9, 1626−33. doi:  10.4161/hv.24846
[50] Diallo AO, Wikswo ME, Sulemana I, et al. Rotavirus vaccine effectiveness against severe acute gastroenteritis: 2009-2022. Pediatrics, 2024; 154, e2024066879. doi:  10.1542/peds.2024-066879
[51] Bennett A, Pollock L, Bar-Zeev N, et al. Community transmission of rotavirus infection in a vaccinated population in Blantyre, Malawi: a prospective household cohort study. Lancet Infect Dis, 2021; 21, 731−40. doi:  10.1016/S1473-3099(20)30597-1
[52] Standaert B, Strens D, Raes M, et al. Explaining the formation of a plateau in rotavirus vaccine impact on rotavirus hospitalisations in Belgium. Vaccine, 2022; 40, 1948−57. doi:  10.1016/j.vaccine.2022.02.053